Celularity FY25 operating loss widens to $61.31 million; revenue drops 51% to $26.55 million

• Celularity posted a net loss of $91.72 million for 2025.
• Revenue fell 51% to $26.55 million, driven by a 62.7% drop in product sales to $13.18 million.
• Operating loss widened 59.8% to $61.31 million as cost of product sales climbed to $12.85 million.
• Liquidity remained tight with cash and cash equivalents of $6.2 million, while net cash used in operating activities increased to $13.25 million.
• Recent moves included a NexGel deal to license certain degenerative disease products for $13.3 million in consideration, while management said cash resources are not sufficient to fund operations for 12 months beyond filing date and it is pursuing additional capital and asset monetizations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-020424), on April 30, 2026, and is solely responsible for the information contained therein.